Chris Morrissey

Freelance senior financial writer and editor

POINT Biopharma ($PNT) Update

We have the results for PNT2002 and no luck I’m afraid, nor any more bids. It was asymmetric with LLY’s offer putting a solid floor underneath us and the potential of these SPLASH results meaning the ceiling for upside was quite high. I’ll mark this down as a free swing that just didn’t come off and move on to fresher pastures. I hope to write up a more ideas in 2024!

https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma

Leave a Reply

Your email address will not be published. Required fields are marked *